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Abstract
Background-: Specific types of high risk Human papillomaviruses (HR-HPVs) particularly, HPV types 16 and 18
cause cervical cancer and while the two recently developed vaccines against these HPV types are prophylactic in
nature, therapeutic options for treatment and management of already existing HPV infection are not available as
yet. Because transcription factor, Activator Protein-1 (AP-1) plays a central role in HPV-mediated cervical
carcinogenesis, we explored the possibility of its therapeutic targeting by berberine, a natural alkaloid derived from
a medicinal plant species, Berberis which has been shown to possess anti-inflammatory and anti-cancer properties
with no known toxicity; however, the effect of berberine against HPV has not been elucidated.
Results-: We studied the effect of berberine on HPV16-positive cervical cancer cell line, SiHa and HPV18-positive
cervical cancer cell line, HeLa using electrophoretic mobility gel shift assays, western and northern blotting which
showed that berberine could selectively inhibit constitutively activated AP-1 in a dose- and time-dependent
manner and downregulates HPV oncogenes expression. Inhibition of AP-1 was also accompanied by changes in
the composition of their DNA-binding complex. Berberine specifically downregulated expression of oncogenic c-
Fos which was also absent in the AP-1 binding complex. Treatment with berberine resulted in repression of E6 and
E7 levels and concomitant increase in p53 and Rb expression in both cell types. Berberine also suppressed
expression of telomerase protein, hTERT, which translated into growth inhibition of cervical cancer cells.
Interestingly, a higher concentration of berberine was found to reduce the cell viability through mitochondria-
mediated pathway and induce apoptosis by activating caspase-3.
Conclusion-: These results indicate that berberine can effectively target both the host and viral factors responsible
for development of cervical cancer through inhibition of AP-1 and blocking viral oncoproteins E6 and E7
expression. Inhibition of AP-1 activity by berberine may be one of the mechanisms responsible for the anti-HPV
effect of berberine. We propose that berberine is a potentially promising compound for the treatment of cervical
cancer infected with HPV.
Background
Cervical cancer is the most frequent malignancy in Indian
women, and is responsible for substantial morbidity and
mortality worldwide [1]. Persistent infection with high-risk
human papillomavirus (HR-HPV), most notably types 16
and 18 is an essential prerequisite for the development of
cervical cancer [2]. During malignant progression, the
HPV integrates into the host cell genome resulting in a
loss of expression of the viral E2 gene and over-expression
of the two early viral oncogenes E6 and E7, the products
of which interfere with the tumor suppressor proteins p53
and Rb respectively. E6 binds and induces ubiquitin
mediated degradation of p53 while E7 inactivate pRb lead-
ing to dysregulated cell growth [3].
The constitutive expression of HR-HPV E6 and E7
oncogene is mainly dependent on the availability of host
cell transcription factors. Activator protein-1(AP-1) which
is a heterodimer of a group of structurally and functionally
related members of the Jun proteins (c-Jun, JunB, JunD)
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be constitutively active in cervical cancer. Mutational inac-
tivation of AP-1 consensus sequence within the binding
sites of the HR-HPV upstream regulatory region (URR)
revealed a complete loss of transcriptional activity of the
E6/E7 promoter indicating a key role of AP-1 in HPV-
mediated carcinogenesis [4]. Interestingly, AP-1 indepen-
dently has also been shown to develop carcinogenesis in a
variety of tissues [5]. Additionally, studies by our group
demonstrated a significant overexpression of constitutively
active AP-1 family members in cervical precancer and
cancer tissues [6].
The most important risk factor in this cancer is the
presence of human papillomavirus (HPV) infection.
Conventional therapies like removal of lesions through
cryo, laser therapy, excisional surgery, or topical applica-
tion of formulations of podophyllotoxin, trichloroacetic
acid and salicylic acid or 5-fluorouracil, including direct
injections of interferon into the lesions may help elimi-
nate the lesions or warts but none of them eradicates
the virus. Consequently, recurrence of the lesions, as
well as transmission of the virus remains a very signifi-
cant problem. Since HR-HPV E6 and E7 are the two
transforming proteins constantly expressed in trans-
formed cells, they represent ideal targets for develop-
ment of anti-HPV therapeutics [7]. Antiviral approach
against transcriptional inactivation of HPV using herbal
derivatives that show minimal or no systemic toxicity
could be a promising option to control HPV infection
particularly in an early stage of cervical carcinogenesis.
Berberine (5, 6-dihydro-9, 10-dimethoxybenzo[g]-1,
3-benzodioxole5,6-aquinolizum) (Figure 1) [8], a natural
isoquinoline alkaloid present in roots, rhizome and
outer bark of an important medicinal plant species,
Berberis (B. aquifolium, B. vulgaris, B. aristata, etc.) has
been reported to exhibit variety of pharmacological,
biochemical and anticancer effects [9]. The medicinal
value of berberine is indicated by its use in the Indian
Ayurvedic, Unani and Chinese systems of Medicine
since time immemorial [10,11]. Berberine has been
shown specifically to suppress the growth of a wide vari-
ety of tumors including leukemia [12], melanoma [13],
epidermoid carcinoma [14], hepatoma [15], oral carci-
noma [16] glioblastoma [17], lung [18], prostate [19]
and gastric carcinoma [20] and does not have toxic
effects on growth and viability of normal cells [14,19,21].
Animal studies have also shown that berberine can sup-
press chemical-induced carcinogenesis [22], tumor pro-
motion [23] and tumor invasion [18,24]. It also acts as a
radiosensitizer of tumor cells but not for normal cells
[25]. Though anticancer activity of berberine has been
demonstrated [26] but how it mediate these effects is not
clearly understood and also, its effect on HPV has not
been reported. Therefore, in the present study, we have
investigated the effect of berberine on HPV positive cer-
vical cancer cells to examine its anti-viral activity. We
show here that both viral transcription and cellular pro-
liferation are strongly affected by berberine which specifi-
cally suppresses HPV transcription and constitutively
active AP-1 in dose and time dependent manner.
Materials and methods
Materials
The HPV16 positive human cervical cancer cell line, SiHa,
HPV18 positive human cervical cancer cell line, HeLa and
the HPV negative human cervical cancer cell line, C33a
were obtained from the American Type Culture Collection
(ATCC), USA and were tested and authenticated prior to
initiation of experiments and periodically checked for PCR
positivity of HPV16 and HPV18 and contaminations to
ensure purity of the cell line. DNA hybridization probes,
pHPV16 represent unit-length of HPV16 DNA [2] cloned
in pBR322, pHPV18 represent unit-length of HPV18 DNA
[6] cloned in pBR322, and pHF-A [6] harboring an
approximately full-length insert of the fibroblast b-actin
gene was kindly provided by L. Kedes (Medical Center,
Palo Alto, CA). Custom synthesized and HPLC purified
Oligos were procured from M/s Microsynth, (Germany);
Polyclonal antibodies to AP-1, hTERT, Caspase-3, Rb,
PARP-1 and Monoclonal antibodies to HPV16E6/18E6,
HPV16E7, HPV18E7, p53 were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). DMEM, FCS,
MTT, and Penicillin-Streptomycin solution were obtained
from Sigma (St Louis, MO). All other reagents were of
analytical molecular biology grades.
Cell culture
Cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM), supplemented with 10% heat- inacti-
vated fetal calf serum and 1% penicillin/streptomycin in
Figure 1 The chemical structure of berberine.S o u r c e :B r i t i s h
booklet on Berberine [8].
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and 5% CO2 at 37°C.
Berberine
Commercially available berberine (Sigma) was freshly dis-
solved in DMSO [maximum concentration, 0.5% (v/v)],
which was then added to complete cell culture medium
prior to addition to subconfluent cells. Cells treated with
vehicle only (DMSO, 0.5% in media) served as control.
Lymphocytes isolation
Peripheral blood lymphocytes were isolated from hepari-
nized blood collected from healthy volunteers by stan-
dard method of Ficoll-Hypaque gradient centrifugation
as described by Bharti et.al [27]. These cells were used
for subsequent MTT assay.
MTT assay
The cytotoxic effects of berberine against SiHa, HeLa,
C33a and Lymphocytes were determined by MTT dye
uptake method. The cells were incubated in triplicate in a
96-well plate in the presence or absence of indicated test
samples in a final volume of 0.1 ml for 24 h, 48 h and 72 h
at 37°C in a CO2 incubator. Thereafter 0.025 ml of MTT
solution (5 mg/ml in PBS) was added to each well. After
2 h incubation at 37°C, lysis buffer (20%SDS 50% Dimethyl
Formamide) was added, and the extract was incubated
overnight at 37°C for solublization of formazan crystals.
The OD at 570 nm was measured using a 96-well multi-
scanner autoreader (Biotek, Winooski,Vermont) with the
lysis buffer serving as blank. The percentage of cell viabi-
lity was calculated using the following formula: Percentage
cell viability = (OD of the experiment samples/OD of the
control) × 100.
RNA Extraction and Northern blotting
The cellular RNA were extracted following treatment of
SiHa and HeLa cells with 0, 50, 100 and 250 μg/ml berber-
ine for 24 h by using TRI Reagent according to the manu-
facturer’s instruction. The quality of RNA was estimated
by electrophoresis using 2 μl of RNA solution on an ethi-
dium bromide-stained 1% agarose gel in 3-[N-morpholino]
propane-sulfonic acid (MOPS) buffer. Concentration of
RNA was estimated by Nanodrop (NanoDrop Tech, USA).
The probes were labeled by the random-priming method
using random primer labelling kit (Genei, Bangalore,
India) and northern blotting was carried out using stan-
dard protocols [28]. Briefly, approximately 15 μgo fR N A
was resolved on 1% agarose- MOPS formaldehyde gel.
Capillary blotted Nylon membrane (IMMOBILON-NY+,
Millipore, Bedford, MA) was then UV crosslinked (Hoefer
UVC 500 ultraviolet crosslinker, Amersham Biosciences)
and washed in 6X SSC, air dried, and finally exposed
in phosphorimager (Fujifilm FLA-5100) after pre-hybridi-
zation and hybridization in Perfect HYB-PLUS (Sigma Inc,
USA) solution as suggested by manufacturer’sp r o t o c o l .
Electrophoretic mobility shift assay
For electrophoretic mobility shift assay (EMSA), the fol-
lowing oligonucleotides were used: AP-1 consensus
sequence 5’-CGCTTGATGACTCAGCCGGAA-3’ [29],
Oct-1 consensus oligonucleotide 5’-TGTCGAATG-
CAAATCACTAGAA-3’[30] and Sp-1 consensus sequence
5’-ATTCGATCGGGGCGGGGCGAG-3’[31]. Cells trea-
ted with different concentration of berberine for different
time intervals were harvested and then nuclear extracts
were prepared as described earlier [6]. The protein con-
centration of the extracts was measured by the spectro-
photometric method using Nanodrop spectrophotometer
ND-100. EMSA was performed using 10 μgo fn u c l e a r
extract as described previously [6]. For supershift assays,
2 μg of polyclonal antibodies (Abs) directed against the
Jun/Fos members (Santa Cruz Biotechnology Inc., Santa
Cruz, CA) were added and the reaction mixture was
further incubated for 45 mins at 4°C. The following anti-
bodies were used: c-Jun (epitope corresponding to amino-
terminal domain of mouse c-Jun p39); JunB (epitope
corresponding to carboxy terminal domain of mouse
JunB); JunD (epitope corresponding to carboxy terminus
of mouse JunD); c-fos (epitope corresponding to a highly
conserved domain of c-fos p62 of human origin); FosB
(epitope corresponding to amino acids within the central
domain of the FosB protein of mouse origin); Fra-1(epi-
tope corresponding to amino terminus of Fra-1 of rat ori-
gin) and Fra-2 (epitope corresponding to carboxy
terminus of Fra-2 of human origin). The DNA-protein
complexes were then resolved on 4.5% nondenaturing
polyacrylamide gel, dried and either exposed overnight to
Kodak X-Omat Films (Kodak India Ltd., India) or visua-
lized by PhosphorImager (Fujifilm FLA-5100) using Multi
Gauge-ver 3.x anlaysis software. The quantitative densito-
metric analysis was performed using Alpha Ease FC
version 4.1.0 (Alpha Innotech Corporation, IL).
Western blotting
W h o l ec e l ll y s a t e( 5 0μg / l a n e )w e r er e s o l v e db yS D S -
PAGE, electrotransferred to Immobilon-P membranes
(Millipore Corporation, Bedford, MA). The membrane
was blocked with 10% non-fat milk and incubated over-
night in PBS with 5% milk, 0.05% Tween-20 and probed
with polyclonal rabbit primary antibodies of the corre-
sponding family members (see Electrophoretic mobility
shift assay for AP-1) at 4°C. These blots were washed,
incubated with HRP- anti-rabbit IgG secondary antibo-
dies and visualized by Luminol detection kit (Santa Cruz
Biotech, USA). Membrane was re-probed for b-actin
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fic proteins to b-actin was calculated.
Flow cytometric analysis of apoptotic cell death by
Annexin V-FITC
Cells were treated with berberine for 24 h. The cells were
then harvested, washed with PBS and incubated with
AnnexinV-conjugated fluorescein isothiocynate (FITC)
and propidium iodide (PI) for cellular staining as described
in AnnexinV-FITC apoptosis detection kit (BD Bio-
sciences) manufacturer’s instructions. The stained cells
were then analyzed by FACS. The number of 10000 events
was acquired and the cells were properly gated for analysis
using FACSAria instrument equipped with Flowjo soft-
ware (Becton-Dickinson Biosciences, San Jose, CA).
Quantitation of Caspase- 3 Activity
The activity of caspase-3 was measured using the active
caspase-3 apoptosis kit (BD Pharmingen, USA) following
the manufacturer’s protocol. Briefly, cells were treated
with different doses of berberine for 24 h or for different
time intervals and were harvested by pooling attached
and detached cells were pelleted with centrifugation at
200 × g for 5 min at 4°C. The cells were permeabilized,
fixed, and stained for active caspase-3 (PE-conjugated) as
described in manufacturer’s protocol (BD Biosciences).
Measurement of mitochondrial membrane potential
Cells were plated onto a 60-mm tissue culture plate at
subconfluent density. After 24 h incubation cells were
exposed to different doses of berberine and incubated with
5 μM JC-1 fluorescence dye for 30 min in CO2 incubator
and washed several times with PBS pre-warmed at 37°C.
Mitochondrial membrane potential was evaluated qualita-
tively under a fluorescence microscope (Olympus IX81)
using 568 nm filter.
Statistical analysis
All experiments were conducted in triplicate for at least
three times. The statistical significance of difference
between control and treated groups was analyzed by the
one- way ANOVA (Holm-Sidak method) (Sigma Stat 3.5,
Systat software Inc., CA). The difference was considered
significant when the p value was less than 0.05.
Results
Berberine selectively downregulates constitutively active
AP-1 in HPV16 positive cervical cancer cells, SiHa
To assess anti-HPV activity of berberine, we investigated
the effect of berberine on AP-1, which is constitutively
active in cervical cancer and plays an indispensable role
in transcriptional regulation of HPV oncogenes. HPV16
positive cervical carcinoma cells, SiHa were treated with
different concentrations of berberine for 24 h and the
nuclear protein (10 μg) extracted were examined for
AP-1 DNA-binding activity by EMSA. Results revealed a
dose-dependent decrease of AP-1 DNA binding activity
in berberine-treated cells (Figure 2A). Inhibition was
apparent at 50 μg/ml and a maximum inhibition was
obtained at 250 μg/ml. Densitometric analysis of the
retarded bands showed a 10 fold decrease in AP-1 DNA-
binding activity. Further analysis of time kinetics of ber-
berine-induced AP-1 inhibition for different time periods
revealed a reduced AP-1 DNA binding activity by 12 h
which declined further and disappeared by 24 h (Figure
2B). Specificity of AP-1 DNA binding was confirmed by
cold competition assay using 100 fold molar excess of a
homologous (AP-1) probe which resulted in disappear-
ance of retarded complex whereas it remained unaffected
by addition of heterologous (Oct-1) probe (Figure 2C).
Similarly, effect of berberine on general transcription was
checked by examining nuclear protein (10 μg) of berber-
ine-treated cells for binding to Sp1, a transcription factor
that is ubiquitously active in majority of cells (Figure 2D).
Results showed no inhibitory effect of berberine on Sp1
DNA binding activity. The results, thus establish that
berberine selectively suppresses constitutively active AP-
1 in a dose and time-dependent manner in cervical
cancer cells.
Berberine alters the heterodimerization pattern of AP-1
and differentially modulates expression of Jun and Fos
family proteins
To determine the effect of berberine on composition of
AP-1 complex and to dissect out the AP-1 protein most
sensitive to berberine treatment, we performed supershift
assays on SiHa nuclear proteins treated with berberine
(250 μg/ml) for 8, 12 and 18 h. Under normal conditions,
AP-1 consists of c-Fos, JunB, and JunD (Figure 2E) in its
active DNA-binding complex and over 60% of the super-
shifted band was formed by c-Fos only, while other two
members, JunB, and JunD, contributed moderately, but
other Fos family members (FosB, Fra-1, Fra-2) as well as
c-Jun did not participate in active AP-1 complex. Inter-
estingly, nuclear protein extracted from berberine treated
SiHa cells after 12 h displayed exclusive involvement of
JunB in the binding activity (~70%) with no involvement
of either JunD/c-Jun or any of c-Fos family members in
active AP-1 complex (Figure 2E). These results suggest
that berberine-induced AP-1 inhibition is primarily
mediated through exclusion of c-Fos family of proteins
and JunD from active AP-1 complex whereas JunB DNA
appears to form homodimer.
In order to assess the possibility of decreased involve-
ment of c-Fos and JunD in active AP-1 complex could be
due to their reduced expression, we analyzed expression
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time intervals following berberine treatment. As shown
in Figure 2F, berberine-treated cells demonstrated
reduced expression of c-Fos but interestingly though
JunD also showed reduced expression by 12 h of treat-
ment, its expression got recovered by 24 h. On the other
hand, a compensatory and marginal increase in the
expression of JunB was observed in berberine-treated
cells. These results, therefore, indicate berberine-induced
inhibition of AP-1 is primarily mediated through inhibi-
tion of c-Fos expression and its exclusion from active
complex in cervical cancer cells.
Berberine inhibits AP-1 activity and reduces the
expression of c-Jun and c-Fos in HPV18 positive cervical
cancer cells
We further looked into the effect of berberine on AP-1
activity in cervical cancer cells, HeLa that harbor HR-
HPV18 infection and also express constitutively active
AP-1. Nuclear proteins of HeLa cells which were treated
with varying concentrations of berberine demonstrated a
similar specific dose-dependent inhibition of AP-1 DNA
binding by EMSA (Figure 3A, B). HeLa cell nuclear pro-
teins were also examined for the composition of activated
AP-1 complex by supershift assays revealed presence of
A
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Figure 2 Berberine specifically inhibits AP-1 DNA binding activity in HPV-16 positive cervical cancer cells. SiHa cells treated with indicated
concentrations of berberine for 24 h (A), or treated with 250 μg/ml berberine for indicated durations (B) were assayed for AP-1 DNA binding activity
by EMSA and fold change in DNA binding was calculated by densitometric evaluation of shifted band. C, Binding of AP-1 to its consensus oligo probe is
specific. Untreated SiHa nuclear proteins and labeled AP-1 probe were incubated in the presence of 100 fold molar excess of unlabeled homologous
AP-1 probe or heterologous Oct-1 probe and assayed for AP-1 specific binding by EMSA. D, Berberine does not alter basal activity of other ubiquitous
transcription factor Sp1. Nuclear proteins (10 μg) of berberine- treated cells were checked for Sp1 DNA binding activity by EMSA. E, Effect of Berberine
on composition of AP-1 in DNA-binding complex. Nuclear proteins of berberine (250 μg/ml) treated cells for different time periods were checked for
various AP-1 proteins present in functional AP-1 complex by supershift assay (*Excess of nuclear proteins of 18 h treated cells were used to reveal
participation of AP-1 members.) F, Effect of berberine on the expression of AP-1 family proteins. Cellular proteins isolated from berberine (250 μg/ml)
treated SiHa cells for indicated time durations were examined for the expression of AP-1 family proteins members. b-actin was used as loading control.
The abundance ratio to b-actin was analyzed by densitometry. The data are expressed as the mean ± SD of 3 independent experiments.
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Page 5 of 14c-Jun, JunB, JunD and c-Fos (Figure 3C) in active AP-1
complex whereas FosB, Fra-1,and Fra-2 showed no parti-
cipation in the AP-1 complex formation. As compared to
SiHa cells, where there is no involvement of c-Jun, we
have found presence of c-Jun in HeLa cells but to a lesser
extent. To determine the effect of berberine on specific
AP-1 proteins involved in active complex, nuclear protein
of HeLa cells treated with berberine were examined by
supershift assays which displayed exclusive involvement
of JunB and JunD in the binding activity with no involve-
ment of c-Fos (Figure 3C). These results suggest that c-
Fos is the most sensitive AP-1 member and its exclusion
from active AP-1 complex contributes maximally to the
loss of AP-1 activity in berberine-treated cells. Further
investigation of AP-1 protein expression revealed a dose-
dependent loss of c-Fos and c-Jun in berberine treated
cell (Figure 3D). These observations collectively indicated
exclusion of Fos member from active complex and loss
of AP-1 activity are primarily mediated through loss of
expression of c-Fos and c-Jun in berberine-treated cells.
Berberine downregulates HPV16 and HPV18 transcription,
suppressed E6, E7 and hTERT expression and increased
p53 and Rb expression in cervical cancer cells
To investigate, whether inhibition of AP-1 by berberine
has any impact on the viral transcription, total RNA was
Figure 3 Berberine specifically downregulates constitutive active AP-1 in HPV18 positive cervical cancer cells. A, Dose-dependent
downregulation of AP-1 binding activity. Nuclear proteins of HeLa cells treated without or with indicated concentrations of berberine for 24 h
were prepared and assayed for AP-1 DNA binding activity by EMSA. As indicated in “Methods” fold change was calculated following
densitometric evaluation of shifted band. B, Binding of AP-1 to its consensus oligo probe is specific. Binding specificity of AP-1 to its consensus
probe was examined by cold competition in a binding reaction of untreated HeLa nuclear proteins and labeled AP-1 probe adding 100 fold
molar excess of unlabeled homologous AP-1 probe or heterologous Oct-1 probe. C, Berberine changes composition of AP-1 DNA-binding complex
in HeLa cells. Equal amount of nuclear extracts (10 μg/lane) isolated from untreated as well as treated (100 μg/ml berberine for 18 h) HeLa cells
were checked for binding partners in functional AP-1 complex by co-incubating these extracts individually with different antibodies as described
in ‘Methods’. (*Excess of nuclear proteins used to reveal participation of AP-1 members.) D, Effect of berberine on the expression of AP-1 family
proteins. HeLa cells treated with berberine for indicated doses and protein isolated from these cells were subjected to western blot analysis as
described in “Methods”. b-actin was used as loading control. The abundance ratio to b-actin was analyzed by densitometry. The data are
expressed as the mean ± SD of 3 independent experiments.
Mahata et al. Molecular Cancer 2011, 10:39
http://www.molecular-cancer.com/content/10/1/39
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ment with different concentrations of berberine for 24 h
and northern blotting was performed using HPV16-
DNA and HPV18-DNA probes respectively. The results
revealed a concentration dependent decline in HPV16-
specific transcripts in berberine-treated SiHa cells
(Figure 4A). Berberine at 50 μg/ml was found to signifi-
cantly downregulate viral transcription and strongest
reduction was detected in cells treated with 250 μg/ml.
A decline in HPV18-specific transcripts was also
observed in berberine-treated HeLa cells (Figure 4A).
Suppression of HPV transcription was found to be selec-
tive since expression of house keeping gene, b-actin was
not affected in both the cells.
We then proceeded to investigate the expression level
of HPV oncogenes, E6 and E7 after berberine treatment.
Data from western blotting analysis showed that the
expression of HPV16E6, HPV16E7, HPV18E6 and
HPV18E7 were significantly suppressed by berberine in
cervical cancer cells in a dose-dependent manner
(Figure 4B).
The two most essential cell cycle regulators and tumor
suppressor proteins, p53 and Rb being the targets of high-
risk HPV E6 and E7 oncoproteins respectively, we also
examined the status of p53 and Rb expression in SiHa and
HeLa cells. Both of these cervical cancer cells expressed
p53 and Rb at low levels which showed a dose- dependent
increase in expression following treatment with berberine
(Figure 4C).
Since two viral oncoproteins, E6 and E7 encoded by
HR-HPVs contribute to immortalization of primary
human epithelial cells through the induction of telomer-
ase activity by stimulating transcription of the catalytic
subunit of telomerase, hTERT, we examined whether
suppression of HPV transcription and reduced expression
of viral oncogenes due to berberine also result in altered
expression of hTERT. Cellular proteins (50 μg) extracted
from SiHa and HeLa cells were incubated in the absence
or presence of berberine (100 μg/ml for 24 h) was
checked for hTERT expression using western blotting. As
depicted in Figure 4D, high expression of hTERT protein
was observed in untreated cells which decreased signifi-
cantly upon berberine treatment in both the cells.
Berberine decreases cell viability and induce growth
inhibition in cervical cancer cells
Activation of AP-1 along with increased expression of viral
oncoproteins and telomerase are all critical prerequisites
for growth promoting and cell survival mechanisms of cer-
vical cancer cells. Therefore, we were interested to check
how does inhibition of these factors translates onto cell
survival and growth of berberine-treated cells. For this,
cells were treated with different concentration of berberine
for 24 h and their viability was checked by MTT assay. As
indicated in Figure 5A, Treatment of berberine with vary-
ing concentration resulted in concentration-dependent
loss of cell viability of both SiHa and HeLa cells with 50%
inhibitory dose (ID50) of approximately 90 μg/ml for SiHa
and 75 μg/ml for HeLa cells and maximal effect was
observed at 250 μg/ml. SiHa cells were also checked for
their growth kinetics at 24, 48 and 72 h in the absence or
presence of different concentration of berberine. As sum-
marized in SiHa cell growth curves in the presence of ber-
berine (Figure 5B), berberine at as low as 10 μg/ml could
retard the growth of cervical cancer cells. Berberine at
concentration higher than 50 μg/ml resulted in reduced
cell viability drastically and cultures did not recover within
72 h. Though berberine inhibits cell proliferation of HPV
positive cervical cancer cells, however, in case of HPV
negative cervical cancer C33a cells we did not find signifi-
cant inhibitory effect of berberine on cell viability (1-24%
inhibition) (Figure 5A). Treatment of lymphocytes with
berberine also results in a non significant inhibitory effect
on cell viability (1-4%) at the higher concentrations of
berberine (100 μg/ml and 250 μg/ml) after 24 h of treat-
ment (Figure 5A). These data indicates that berberine has
a better cytotoxic effect on HPV positive human cervical
cancer cells.
Berberine-induced growth inhibition is mediated through
induction of apoptosis
To understand the mechanism of berberine-induced
growth inhibition and to examine whether berberine-
induced inhibition of cervical cancer cells was associated
with the induction of apoptosis, SiHa and HeLa cells were
treated with berberine and berberine-induced apoptosis
was assessed using Annexin V-PI staining of the treated
cells that identify specifically the cells undergoing apopto-
tic cell death and start expressing phosphatidylserine on
their cell surface. As shown in Figure 6A, cells treated
with berberine had a very high Annexin V staining and
were also positive for PI, a phenotype generally expressed
by early apoptotic cells when compared to untreated cells.
To further dissect the berberine-induced apoptotic
mechanism, we checked the effect of berberine on Poly
(ADP-ribose) polymerase (PARP-1) cleavage, the down-
stream substrate of active caspase 3. Berberine-treated
whole cell lysates (50 μg) of SiHa and HeLa cells were
probed for the analysis of PARP-1 by western blotting
which showed cleavage of 116 kDa intact PARP-1 into
85 kDa fragment in both the cells (Figure 6B). The
quantitation of cells for active caspase 3 by flow cytome-
try revealed 70% cells positive by 24 h when treated with
100 μg/ml berberine and almost all cells had active cas-
pase-3 when treated with 250 μg/ml of berberine in
SiHa cells (Figure 6C). About 99% cells were positive for
active caspase-3 in HeLa cells treated with 100 μg/ml
berberine for 24 h (Figure 6C).
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Page 7 of 14Figure 4 Berberine downregulates HPV oncogene expression, increased p53, Rb levels and inhibit hTERT expression in cervical cancer
cells. A, Effect of berberine on HPV16 and HPV18 mRNA expression. Northern blots (middle panels) of HPV16 positive SiHa cells and HPV18 positive
HeLa cells incubated with indicated concentrations of berberine. Quantity and quality of total RNA (15 μg/lane) extracted was examined on
agarose gel (upper panels). The membrane was rehybridized with b-actin-specific DNA probe as internal control to assess equal loading (lower
panels). B, Effect of berberine on the expression of HPV E6 and E7 oncoproteins. Representative immunoblots of HPV16E6 &E7 and HPV18E6 &E7 in
SiHa and HeLa cells respectively treated with berberine for indicated doses. b-actin was used as loading control. C, Effect of berberine on the
expression of p53 and Rb proteins. HPV16 positive SiHa cells and HPV18-positive HeLa cells were treated with different concentration of berberine.
The cells were harvested after 24 h to obtain whole cell extracts, which were analyzed for p53 and Rb expression by Western blotting. Equal
sample loading was confirmed by determining the b-actin expression levels. D, Effect of berberine on the expression of hTERT. Immunoblots of
cellular proteins isolated from SiHa and HeLa cells treated with berberine. b-actin was used as loading control. The abundance ratios to b-actin
were analyzed by densitometry. The data are expressed as the mean ± SD of 3 independent experiments.
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Page 8 of 14Since loss of mitochondrial membrane potential is
the primary target for majority of extrinsic apoptotic
signals, we checked the integrity of mitochondrial
membrane using metachromatic dye, 5,5’6,6’ tetra-
chloro-1,1’3,3’ tetraethylbenzimidazolylc iodide (JC-1),
which stains the mitochondria red when their mem-
branes are intact (polarized) whereas they give green
fluorescence with depolarized membranes. Figure 6D
clearly demonstrates that in cells treated with a high
concentration of berberine (Figure 6D, bottom panels)
mitochondria lost their membrane potential and thus
proceeded through apoptosis.
Discussion
Host cell derived transcription factor, AP-1 binds to long
control region or upstream regulatory region (URR) of
HPV, plays an essential role in HPV-mediated host cell
immortalization and oncogenic transformation. Site-
directed mutagenesis of AP-1 binding sites within the
URR regions [32] and stable infection assays in raft cul-
ture [33] have established an indispensible role of AP-1
in initiating and maintaining the expression of two essen-
tial high risk HPV oncoproteins E6 and E7 during cervi-
cal carcinogenesis. Earlier studies from our group and
others have demonstrated overexpression and constitu-
tive activation of AP-1 in cervical cancer cells and the
DNA binding affinity of AP-1, as well as the expression
of its constituent members, varies as a function of the
severity of cervical lesions [6,34]. Thus transcription
factor, AP-1 can be considered as potential therapeutic
targets for cervical cancer. In the present investigation,
we show that a naturally occurring isoquinoline alkaloid,
berberine, selectively suppress expression of AP-1 tran-
scription factor in a dose and time dependent manner.
Inhibition of AP-1 was accompanied by suppression
of HPV transcription and oncogene expression as well
as inhibition of downstream telomerase component,
hTERT. Berberine-mediated inhibition of growth pro-
moting signals culminated in growth inhibition and loss
of cell viability through induction of apoptosis in cervical
cancer cells. Our results demonstrated a dose-dependent
selective suppression of AP-1 activity by berberine which
was accompanied by suppression of c-Fos and JunD
expression and their reduced involvement in functional
AP-1 complex in HPV positive cervical cancer cells irre-
spective of infecting HR-HPV types whereas JunB that
also participated in an active AP-1 complex remained
unaffected. Comparison between the two cell lines
revealed a specific effect of berberine on c-Fos and c-Jun
resulting in their exclusion from the functional AP-1
complex which could be partly due to downregulation of
their respective expression levels. Earlier studies also
described berberine-induced inhibition of AP-1 in mur-
ine tumor models as well as hepatic, breast and oral can-
cer cells [16,24,35], but the mechanism of its inhibition
remained unclear. Recent study shows that inhibitory
effect of berberine could be mediated through inhibition
of c-Jun that suppresses expression of downstream gene,
cyclin D1 and results in cell cycle arrest [36]. However, in
HPV16 positive SiHa cells or HPV18 positive HeLa cells
it appears that berberine is not executing its effect
through this mechanism as involvement of c-Jun in active
AP-1 is negligible [6]. On the contrary, expression of
c-Fos which is the major partner of active AP-1 dimer
was the target of berberine and was found to be the most
sensitive among all AP-1 proteins. Although further
Figure 5 Berberine treatment results in dose-dependent loss of
cell viability and induces growth inhibition in cervical cancer
cells. A, Percent cell viability of cells treated with berberine for 24 h.
Cervical cancer cells and normal peripheral blood lymphocytes were
treated with indicated doses of berberine in triplicates and the
viability was measured at different time intervals by MTT assay as
described in “Methods”. B, Growth curve of berberine-treated SiHa
cells at different time points reflecting cytotoxic and cytostatic effects
at different concentration. Error bars indicates SD.
ap- < 0.001 is
compared to untreated control at 24 h,
bp- < 0.001 is compared to
untreated control at 48 h,
cp- < 0.001 is compared to untreated
control at 72 h.
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Page 9 of 14experiments using selective inhibition of c-fos and JunD
by specific siRNA or reporter assays comparing the dif-
ferent homodimers and heterodimers of Jun and Fos
family members are required to validate the significance
of altered AP-1 composition, the present observations do
support berberine as a preferred anti-HPV therapeutic
molecule for cervical carcinogenesis. Rapidly growing
amount of data from experimental, clinical and animal
studies reveal that c-Fos appears to have strong onco-
genic activity and is frequently overexpressed in almost
all tumor cells [5]. Our earlier study demonstrated c-Fos
as a major AP-1 member which showed high expression
in cervical carcinogenesis [6]. In an ingenious experiment
where c-Fos was ectopically over expressed through
stable transfection of nontumorigenic HeLa-fibroblast
hybrid 444 cells, it induced tumorigenity. This reiterates
the tumorigenic role of c-Fos [37]. AP-1 has been shown
to be an important target for anti-oxidant mediated
action on cervical cancer cells [28]. However, the
mechanism of their action may differ as antioxidants like
PDTC enhances AP-1 binding and elicits up-regulation
of c-Fos and c-Jun expression. Instead of acting directly
on c-Fos it results in upregulation of Fra-1 which has
antagonistic role to c-Fos and prevents its involvement in
formation of functional AP-1 complex [28]. Though the
mechanism(s) underlying berberine-induced inhibition of
c-Fos expression is unclear, studies on vascular smooth
muscle cells demonstrated that berberine can inhibit c-
Fos expression by inhibiting ERK1/2 [38,39], the
upstream kinases responsible for c-Fos expression
through transcription factor TCF/Elk-1 [40].
The gradual but distinct increase in JunB protein
expression after berberine treatment strongly support the
tumor suppressor activity of JunB as it was earlier
reported that JunB and JunD can negatively regulate cell
proliferation [41] and has an opposite effect on gene
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Figure 6 Berberine induces apoptosis, activation of Caspase 3 and loss of mitochondrial membrane potential in cervical cancer cells.
A, Flowcytometric analysis of SiHa and HeLa cells treated with berberine for 24 h. Treated cells were examined for apoptotic cells using Annexin V-
FITC apoptosis detection kit. B, Immunoblot analysis of cellular protein isolated from SiHa and HeLa cells treated with berberine for PARP-1
expression as described in “Methods”. C, Flowcytometric analysis of SiHa and HeLa cells for active caspase-3. Percentage in histograms shows
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Page 10 of 14expression. Furthermore, JunB is also known to be a
weaker transactivator than c-Jun [42]. Though JunB is
essential for the HPV18 P105 promoter activation [32],
there may be possibility that interaction with other pro-
teins may inhibit DNA binding due to direct protein-pro-
tein interaction [43] thus, negative interference between
proteins, either c-Jun or JunD may be one of the reasons
of decrease in AP-1 DNA binding activity.
Our results indicate that berberine can effectively sup-
press HPV transcription and thus could inhibit the
expression of its two oncogenes, E6 and E7 that are cri-
tically involved in cellular transformation. Spatial and
temporal expression of these viral genes is tightly con-
trolled by specific cognate sequences in URR that bind
specific transcription factors of the host cells. The
sequence analysis of viral URR region which controls
the expression of these oncogenes demonstrates pre-
sence of multiple AP-1 binding sites [44] and thus indi-
cates a direct involvement of this transcription factor in
oncogenic transformation. Suppression of HPV tran-
scription by berberine, therefore, could be the direct
outcome of inhibited AP-1 activation in cervical cancer
cells. Apart from targeting p53 and pRB, E6 and E7
have been demonstrated to induce transcription of
hTERT, the active component of telomerase responsible
for its catalytic activity [45]. Berberine-induced inhibi-
tion of viral transcription was associated with sup-
pressed hTERT expression; hence berberine could also
target telomerase activity in cervical cancer cells, which
we have shown earlier to be an important marker for
cervical carcinogenesis [46]. Earlier study on human leu-
kemia cells also provided the evidence that berberine
could inhibit telomerase by directly inhibiting expression
of its components nucleophosmin/B23 [47] and thus
could effectively suppress overall activity independent of
HPV involvement. Collectively these observations indi-
cate that berberine could effectively target survival
advantage rendered by telomerase expression in HPV-
infected cervical cancer cells and could suppress cell
proliferation.
In addition to its inhibitory effects on HPV transcrip-
tion, berberine also antagonizes cell proliferation. Our
results demonstrate two distinct concentration-depen-
dent growth inhibitory effects of berberine on cervical
cancer cells. Berberine at 50 μg/ml or lower suppressed
proliferation whereas at concentration higher than 50
μg/ml resulted in dose-dependent apoptosis. Similar
concentration-dependent biphasic effects have been
reported earlier [48]. Similar to the cytotoxic/cytostatic
effect of berberine observed in present investigation
especially in cancer cell lines in contrast to normal lym-
phocytes, a comparative analysis of studies performed
on various human cancer cell lines and primary cultures
using purified berberine revealed a differential sensitivity
of various cancer cell types whereas normal cells
remained unaffected (Table 1). Interestingly, majority of
studies performed on cervical cancer cells showed
requirement of high concentration of berberine for man-
ifestation of its cytotoxic effect [26,49,50] which could
be ascribed to viral etiology of cervical cancer and over-
expression of viral oncoproteins E6 and E7 that may
effectively override cellular checkpoints. However, it was
also observed that the effective cytotoxic doses were
always less in HPV positive cells as compared to HPV
negative cervical cancer cell, C33a that have undergone
cellular transformation independent of viral infection.
The reason for such a dichotomy in berberine’s effect in
cervical cancer cells is unclear.
The anti-proliferative and apoptotic activity of berberine
have been attributed to its concentration-dependent selec-
tive accumulation in mitochondria at lower concentration
and nuclear as well as cytoplasmic accumulation at higher
mitochondria-saturating doses that could interfere with
DNA synthesis, perturb cell cycle and sufficient to trigger
apoptosis. Our long term cultures of berberine-treated
cells also demonstrated a suppressed growth at low doses
without any prominent cell death component. Since ber-
berine is a substrate of ATP-driven drug efflux pump [51],
it is likely that at saturating concentrations berberine
reduces the energy levels of the mitochondria below criti-
cal levels resulting in triggering of programmed cell death.
This assumption gets strength from the experiments
showing berberine effectively synergizes with drug efflux
pump inhibitors [52]. Some investigators propose berber-
ine’s DNA-binding activity[53] could be responsible for
rapid inhibition of DNA synthesis of berberine-treated
cells and cell cycle arrest in S phase and G2/M phase [20].
Apart from these direct actions of berberine its inhibitory
action on viral oncoproteins (E6/E7) expression via inhibi-
tion of AP-1 could be primarily responsible for growth
suppression and induction of apoptosis in HPV positive
cervical cancer cells. Our observations together with con-
firmatory annexin V analysis, suggest berberine could
antagonize multiple survival and growth promoting
mechanisms operating in cervical cancer cells and can
induce apoptosis in a dose-dependent manner.
The key biochemical event involved in the induction of
apoptosis is activation of caspase3 which is mediated
through proteolytic cleavage of procaspase3 via upstream
caspases (caspase7/9 or caspase 8). Berberine-treated
cells demonstrated activation of caspase3 which also cor-
roborated with proteolytic cleavage of its substrate
PARP-1 as early as 6 hours. These apoptotic events were
found associated with loss of mitochondrial membrane
potential which is the primary mechanism of action of
many chemotherapeutic/chemopreventive agents as well
as other external apoptotic stimuli [54]. This event is suf-
ficient to release cytochrome C from mitochondrial
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Page 11 of 14Table 1 Comparative analysis of in vitro studies performed for assessing anti-cancer properties of purified berberine
(>99%) in various human cancer and normal cells
Cells Type (Human) Cell Line Concentration Range
Tested
Percent Cell Death at max. Dose after 24
h (Approx; %)
IC50 (μg/ml)
after 24 h
References
μM μg/ml
Tongue squamous
carcinoma
SCC-4 15 - 100 5.58 - 37 45 28 (48 h) [55]
Prostrate carcinoma LNCaP 10 - 100 3.7 - 37 35 >37 [19]
5 - 100 1.8 - 37 65 22.3 [56]
DU145 10 - 100 3.7 - 37 40 >37 [19]
PC-3 10- 100 3.7 - 37 70 18.6 [19]
5 - 100 1.8 - 37 50 37 [56]
Oral squamous cell
carcinoma
HSC-3 5 - 75 1.8 - 28 82 6.7 [57]
Non-small cell lung
carcinoma
A549 25 - 100 9.3 - 37 55 28 [21]
H1299 25 - 100 9.3 - 37 50 (48 h) 37 (48 h) [21]
Nasopharyngeal
carcinoma
5-8F 2.5 - 100 0.93 - 37 50 37 [58]
Leukemia HL-60 5 - 60 1.8 -22 70 <11 [59]
Hepatoma KIM-1 0.01 - 100 0.0037 - 37 35 14.88 [35]
Hep3B 0.32- 320 0.119 - 119 8.5 Not defined [60]
HA22T/VGH 0.32 - 320 0.119 - 119 1 Not defined [60]
HepG2 28 - 107 10 - 40 95 13 (48 h) [61]
1 - 10 0.37 - 3.7 70 0.52 [62]
0.32 - 320 0.119 - 119 6 ND [60]
Glioma U87 1 -20 1 - 7.4 40 >7.4 [63]
T98G 134 - 538 50 - 200 60 134 [17]
Gastric carcinoma SNU-5 50 - 200 18.6 - 74 95 17.85 [20]
Embryonic kidney HEK-293T 1 - 10 0.37 - 3.7 35 5 [62]
Epidermoid carcinoma A431 5 - 75 1.8 - 28 45 >28 [14]
Breast carcinoma MDA-MB-231 1 - 10 1 - 3.7 0 Not defined [24]
Cervical carcinoma C33a (HPV-) 2.7 - 672 1 - 250 24 >250 Current
study
CaSki (HPV16+) 50 - 150 18.6 - 55.8 80 42 [26]
SiHa (HPV16+) 2.7 - 672 1 - 250 87 90 Current
study
HeLa (HPV18+) 0.27 - 403 0.1 - 150 ND 6 [49]
0.1 - 10 0.037 - 3.7 No effect Not defined [64]
33.5 - 269 12.5 - 100 50 100 [50]
1 - 10 0.37 - 3.7 48 4 [62]
2.7 - 672 1 - 250 90 75 Current
study
Normal Cells Bronchial
epithelium
25 - 100 9.3 - 37 5 No effect [21]
Lymphocytes 2.7 - 672 1 - 250 4 No effect Current
study
Prostrate
epithelium
(PWR-1E)
5 - 100 1.8 - 37 40 Not defined [56]
10 - 100 3.7 - 37 5 No effect [19]
Epidermal
keratinocytes
5 - 75 1.8 - 28 11 (48 h) No effect [14]
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Page 12 of 14membrane and execute proteolytic activation of caspases.
Nonetheless, direct mitochondrial tropism of berberine
through induction of GADD153 levels [26] could also
have directly contributed to the loss of mitochondrial
potential. Though there could be multiple direct or indir-
ect mechanisms, these observations collectively indicate a
potential role of mitochondria in berberine-induced
apoptosis.
Conclusions
In view of potential anti-HPV activity displayed by ber-
berine through inhibition of constitutively active AP-1
as well as its selective, anti-proliferation and cytotoxic
effects coupled with pharmacological safety in human,
berberine appears to be a promising therapeutic agent
for the treatment of cervical cancers.
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